| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XYL | Common Stock | Award | $906K | +7.08K | +58.48% | $127.94 | 19.2K | Mar 1, 2024 | Direct | F1, F2 |
| transaction | XYL | Common Stock | Tax liability | -$54.8K | -428 | -2.23% | $127.94 | 18.8K | Mar 1, 2024 | Direct | F3 |
| transaction | XYL | Common Stock | Options Exercise | $991K | +9.7K | +51.67% | $102.23 | 28.5K | Mar 1, 2024 | Direct | |
| transaction | XYL | Common Stock | Sale | -$1.23M | -9.7K | -34.07% | $127.14 | 18.8K | Mar 1, 2024 | Direct | F4 |
| transaction | XYL | Common Stock | Options Exercise | $437K | +5.04K | +26.82% | $86.76 | 23.8K | Mar 1, 2024 | Direct | |
| transaction | XYL | Common Stock | Sale | -$640K | -5.04K | -21.15% | $127.14 | 18.8K | Mar 1, 2024 | Direct | F4 |
| transaction | XYL | Common Stock | Sale | -$619K | -4.87K | -25.95% | $127.14 | 13.9K | Mar 1, 2024 | Direct | F4 |
| transaction | XYL | Common Stock | Options Exercise | $493K | +4.88K | +35.07% | $101.09 | 18.8K | Mar 1, 2024 | Direct | |
| transaction | XYL | Common Stock | Sale | -$620K | -4.88K | -25.97% | $127.17 | 13.9K | Mar 1, 2024 | Direct | F4 |
| transaction | XYL | Common Stock | Sale | -$580K | -4.55K | -32.71% | $127.53 | 9.35K | Mar 5, 2024 | Direct | F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XYL | Non-Qualified Stock Option (Right to Buy) | Options Exercise | $0 | -9.7K | -100% | $0.00* | 0 | Mar 1, 2024 | Common Stock | 9.7K | $102.23 | Direct | F6 |
| transaction | XYL | Non-Qualified Stock Option (Right to Buy) | Options Exercise | $0 | -4.88K | -33.33% | $0.00 | 9.75K | Mar 1, 2024 | Common Stock | 4.88K | $101.09 | Direct | F7 |
| transaction | XYL | Non-Qualified Stock Option (Right to Buy) | Options Exercise | $0 | -5.04K | -50% | $0.00 | 5.04K | Mar 1, 2024 | Common Stock | 5.04K | $86.76 | Direct | F8 |
| transaction | XYL | Stock Options (Right to buy) | Award | $1.01M | +7.93K | $127.94 | 7.93K | Mar 1, 2024 | Common Stock | 7.93K | $127.94 | Direct | F9 |
| Id | Content |
|---|---|
| F1 | Reflects the acquisition of 4,739 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ROIC (2,934) and Total Shareholder Return (1,805). Reflects an award of 2,345 restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016) that are scheduled to vest in one third increments on March 1, 2025, March 1, 2026 and March 1, 2027. |
| F2 | Includes additional shares due to dividend reinvestment. |
| F3 | Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2021 (252) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016). Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2021 (39), March 1, 2022 (62), and March 1, 2023 (75) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016). |
| F4 | This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). These Shares were executed at a range of prices from $127.03 to $127.30. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. |
| F5 | This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). These Shares were executed at a range of prices from $127.10 to $127.55. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. |
| F6 | The March 1, 2021 option grant vested 3,201 options on March 1, 2022, 3,265 options on March 1,2023, and 3,232 options on March 1, 2024. |
| F7 | The March 1, 2023 option grant vested 4,875 options on March 1, 2024, and will vest 4,875 options on March 1, 2025, and 4,875 options on March 1, 2026. |
| F8 | The March 1, 2022 option grant vested 5,035 options on March 1, 2023, 5,035 options on March 1, 2024, and will vest 5,036 options on March 1, 2025. |
| F9 | Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2025, March 1, 2026 and March 1, 2027. |